UK markets open in 1 hour 31 minutes

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.5000-0.7500 (-23.08%)
At close: 10:14AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 349.96M
Enterprise value 242.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)15.47
Price/book (mrq)8.56
Enterprise value/revenue 15.00
Enterprise value/EBITDA -5.61

Trading information

Stock price history

Beta (5Y monthly) 0.88
52-week change 3-64.29%
S&P500 52-week change 3-11.09%
52-week high 329.8500
52-week low 31.3200
50-day moving average 33.2350
200-day moving average 34.0462

Share statistics

Avg vol (3-month) 33
Avg vol (10-day) 320
Shares outstanding 5107.86M
Implied shares outstanding 6N/A
Float 88.54M
% held by insiders 152.20%
% held by institutions 138.20%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022

Profitability

Profit margin -231.35%
Operating margin (ttm)-277.66%

Management effectiveness

Return on assets (ttm)-29.82%
Return on equity (ttm)-264.65%

Income statement

Revenue (ttm)17.5M
Revenue per share (ttm)0.54
Quarterly revenue growth (yoy)39.60%
Gross profit (ttm)6.62M
EBITDA -48.28M
Net income avi to common (ttm)-40.49M
Diluted EPS (ttm)-0.4800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.14M
Total cash per share (mrq)1.98
Total debt (mrq)446k
Total debt/equity (mrq)2.02
Current ratio (mrq)4.41
Book value per share (mrq)0.61

Cash flow statement

Operating cash flow (ttm)-45.46M
Levered free cash flow (ttm)-26.39M